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Abstract
Diabetes is strongly linked to the development of Alzheimer’s disease (AD), though the mechanisms for this enhanced risk 
are unclear. Because vascular inflammation is a consistent feature of both diabetes and AD, the cerebral microcirculation 
could be a key target for the effects of diabetes in the brain. The goal of this study is to explore whether brain endothelial 
cells, injured by diabetes-related insults, glucose and hypoxia, can affect inflammatory and activation processes in microglia 
in vitro. Human brain microvascular endothelial cells (HBMVECs) were either treated with 5 mM glucose (control), 30 mM 
glucose (high glucose), exposed to hypoxia, or exposed to hypoxia plus high glucose. HBMVEC-conditioned medium was 
then used to treat BV-2 microglia. Alterations in microglia phenotype were assessed through measurement of nitric oxide 
(NO), cytokine production, microglial activation state markers, and microglial phagocytosis. HBMVECs were injured by 
exposure to glucose and/or hypoxia, as assessed by release of LDH, interleukin (IL)-1β, and reactive oxygen species (ROS). 
HBMVECs injured by glucose and hypoxia induced increases in microglial production of NO, tumor necrosis factor-α 
(TNFα) and matrix metalloproteinase (MMP)-9. Injured HBMVECs significantly increased microglial expression of CD11c 
and CLEC7A, and decreased expression of the homeostatic marker P2RY12. Finally, bead uptake by BV-2 cells, an index 
of phagocytic ability, was elevated by conditioned media from injured HBMVECs. The demonstration that injury to brain 
endothelial cells by diabetic-associated insults, glucose and hypoxia, promotes microglial inflammation supports the idea 
that the cerebral microcirculation is a critical locus for the deleterious effects of diabetes in the AD brain.
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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder 
characterized by progressive loss of cognitive function, lead-
ing to dementia and death (Lane et al. 2018). AD is a com-
plex, multifactorial disorder where disparate processes likely 
converge to produce neuronal injury. Cardiovascular risk 
factors (CVRFs) are important risk factors for the develop-
ment of AD (Hofman et al. 1997; Helzner et al. 2009; Dick-
stein et al. 2010; Tolppanen et al. 2012; Yaffe et al. 2014). In 
particular, individuals with type 2 diabetes mellitus (T2D) 
have a greater than 50% increased risk for developing AD 
( Ott et al. 1999; Janson et al. 2004; Gudala et al. 2013). In 
the periphery, diabetes and other CVRFs are potent drivers 
of inflammation (Lontchi-Yimagou et al. 2013). Because 
neuroinflammation is a consistent feature of AD, and other 
neurodegenerative diseases, inflammation could be a key 
target for the effects of diabetes in the brain.
Sustained hyperglycemia, a pathognomonic feature of 
diabetes, has been shown to drive endothelial cell dysfunc-
tion in the periphery via a number of signaling mechanisms, 
including increased expression of reactive oxygen species 
(ROS) and inflammatory proteins (Blake and Trounce 
2014; Eelen et al. 2015; Stefano et al. 2016). Microvascular 
endothelial cells at the blood-brain interface are the cells 
in the brain most directly exposed to the deleterious effects 
of high glucose levels. In this regard, both in vitro models 
utilizing high glucose conditions and in vivo experiments 
with diabetic animals have shown compromised blood-brain 
barrier (BBB) integrity and increases in inflammatory pro-
teins, including tumor necrosis factor-α (TNFα), and matrix 
metalloproteinase (MMP)-9 (Bogush et al. 2017; Rom et al. 
2019) .
There is a similar robust elevation in the expression of 
inflammatory mediators in the cerebral microcirculation 
in AD. AD brain endothelial cells express high levels of 
inflammatory adhesion molecules, such as monocyte che-
moattractant protein-1 (MCP-1), intercellular adhesion 
molecule-1 (ICAM-1), and cationic antimicrobial pro-
tein 37 kDa (CAP37) (Frohman et al. 1991; Pereira et al. 
1996; Grammas and Ovase 2001). Additionally, AD brain 
microvessels release significantly higher levels of nitric 
oxide (NO), thrombin, TNFα, transforming growth factor-β 
(TGF-β), interleukin (IL) IL-1β, IL-6, IL-8, and MMPs 
compared to age-matched controls (Dorheim et al. 1994; 
Grammas and Ovase 2001; Grammas and Ovase 2002; 
Thirumangalakudi et al. 2006). Because the inflamed/dam-
aged cerebral endothelium is a highly synthetic interface 
that produces numerous bioactive factors, it is likely that 
endothelial-derived products will have critical effects on 
neighboring cells of the neurovascular unit (NVU) (McCo-
nnell et al. 2017). The functional interaction of NVU cells 
through bidirectional cell-cell signaling is critical for main-
taining cerebral blood flow and regulating physiologic pro-
cesses in the CNS (Muoio et al. 2014). Microglia-endothelial 
cell cross-talk can influence BBB function and permeability 
(Presta et al. 2018). For example, microglia activated by 
treatment with LPS can induce alterations in brain endothe-
lial cell morphology and function (Dudvarski Stankovic 
et al. 2016), but less is known about endothelial cell effects 
on microglia.
Microglia, the brain’s resident immune cells, are key 
drivers of the neuroinflammatory response in AD and other 
neurodegenerative disorders (Akiyama et al. 2000; Calsolaro 
and Edison 2016). Once described as existing in a quiescent 
or resting state, microglia are now understood to be dynamic 
cells that are constantly surveying their microenvironment 
for injury-inducing mediators (Hanisch and Kettenmann 
2007). Microglia are believed to assume a diversity of phe-
notypes in response to noxious extracellular stimuli (Chitnis 
and Weiner 2017; Hickman et al. 2018). Multiple groups 
have identified a disease associated microglia (DAM) or 
microglial neurodegenerative phenotype (MGnD), which 
is present in AD (Keren-Shaul et  al. 2017; Krasemann 
et al. 2017). These DAM show decreased expression of 
homeostatic microglia genes, including p2ry12/p2ry13 and 
tmem119, and increased expression of pro-inflammatory and 
AD-associated genes, including apoe, clec7a, and cd11c. 
Additionally, proliferation and activation of microglia in the 
brain, concentrated around amyloid plaques, is a prominent 
feature of AD (Matsuoka et al. 2001; Fakhoury 2018), and 
a number of recently identified AD-risk genes are related 
to regulation of microglia and the innate immune system, 
including triggering receptor expressed on myeloid cells 2 
(TREM2) (Jones et al. 2010; Guerreiro et al. 2013; Jonsson 
et al. 2013; Lambert et al. 2013). These findings suggest that 
shifts in microglia function and phenotype are a key part of 
the pathological development of AD.
The goal of this study is to explore whether injured 
brain endothelial cells can affect inflammatory and activa-
tion processes in microglia. In our in vitro system, cultured 
brain endothelial cells are injured by exposure to stimuli 
that are important in the development of diabetic pathology, 
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namely high glucose and hypoxia. The ability of conditioned 
media from these injured endothelial cells to alter microglial 
inflammatory proteins, activation markers, and phagocytic 
activity is assessed in order to test the hypothesis that brain 
endothelial cell injury will promote pro-inflammatory acti-
vation of microglia.
Methods
Cell Culture and Other Reagents
Human brain microvascular endothelial cells (HBMVECs- 
ACBRI 376) and complete medium with recombinant 
growth factors (4Z0-500) were purchased from Cell Systems 
(Kirkland, WA, USA). Murine immortalized microglia (BV-
2) were kindly provided by Dr. Navindra Seeram (University 
of Rhode Island, Kingston, RI, USA). Low-glucose Dulbec-
co’s Modified Eagle Medium (DMEM), cell culture grade 
D-glucose (glucose), antibiotic/antimycotic (Ab/Am), Fetal 
Bovine Serum (FBS), and Bovine Serum Albumin (BSA) 
were purchased from Sigma Aldrich (St. Louis, MO, USA).
Culture and Treatment of HBMVECs and BV‑2
HBMVECs were grown to confluence in culture in com-
plete medium in accordance with protocols described by 
Cell Systems and maintained at 37 °C in 5%  CO2 in com-
plete medium. Media was switched to low glucose (5mM) 
DMEM with 1% BSA for treatments. HBMVECs were incu-
bated with low glucose (5mM) (control) or high glucose 
(30mM) in treatment media for 6 h. Cells were maintained 
in normoxia for the full 6 h, or were exposed to hypoxic 
(1%  O2) conditions for the final 1 h of treatment. Following 
treatment, conditioned media were collected and centrifuged 
briefly at 1000×g in sterile conditions to pellet debris, and 
used for subsequent treatment of BV-2.
BV2 were maintained at 37 °C in 5%  CO2 in low glucose 
(5mM) DMEM with 10% FBS, 1% Ab/Am, and 250 nM 
L-glutamine added. HBMVEC-conditioned media was used 
to treat BV-2 for 24 h. Conditioned media were collected 
following endothelial cell treatment with either 5 mM glu-
cose (6 h) (EC-C), 30 mM glucose (6 h) (EC-G), exposure 
to hypoxia (1 h) (EC-H), or exposure to hypoxia plus high 
glucose (6 h) (EC-G+H).
Cytotoxicity Assay
Cellular damage of HBMVECs was assessed by measur-
ing lactate dehydrogenase (LDH) release in the conditioned 
medium. Following treatment, supernatant was transferred 
to a clear 96-well plate and total LDH was assessed using 
the cytotoxicity detection kit (Millipore Sigma, Burlington, 
MA, USA). Absorbance values were read at 490nm follow-
ing incubation with supplied chromogenic dye and catalyst 
using a Synergy HTX multi-mode reader (Biotek Instru-
ments, Winooski, VT, USA).
Detection of Reactive Oxygen Species (ROS)
The production of ROS by HBMVECs was determined by a 
fluorescent probe, 2’,7’-Dichlorofluorescin diacetate (DCF-
DA), using a previously described method with modifica-
tion (Ma et al. 2017). HBMVECs were seeded in a black-
walled, clear-bottom 96-well plate at a density of 100,000 
cells per mL and allowed to grow for 36 h. Cells were then 
treated as previously described with high glucose with or 
without hypoxia for 6 h. Following the 6 h treatment, DCF-
DA (10µM) was added to each well and incubated at 37 °C 
in the dark for 25 min (min). Cells were washed 3 times with 
phosphate buffered saline (PBS). The fluorescence signal of 
each well was measured at 495 nm (excitation) and 529nm 
(emission) using a SpectraMax M2 plate reader (Molecular 
Devices, Sunnyvale, CA, USA).
Griess Assay
The production of NO was determined using the Griess 
reagent system. BV-2 were grown in clear 24-well plates 
at 100,000 cells/mL. Following treatment with HBMVEC-
conditioned media for 24 h, culture media was transferred 
to a clear 96-well plate and total NO was assessed using the 
Griess reagent kit (Promega, Fitchburg, WI, USA). Absorb-
ance values were read at 535nm using a Synergy HTX multi-
mode reader (Biotek Instruments, Winooski, VT, USA).
Western Blot
Following treatments, BV-2 cells were rinsed in ice-cold 
PBS and lysed in 10mM Tris-HCl, 150mM NaCl buffer con-
taining protease inhibitors. Lysates were mixed with 40% 4× 
Sample Buffer (4× Laemmli Sample Buffer (BioRad, Hercu-
les, CA, USA) with 10% 2-mercaptoethonal) and heated to 
100 °C for 10 min. Samples were resolved by SDS-PAGE on 
4–20% Novex gradient gels (Invitrogen, CA) transferred to 
nitrocellulose membranes (iBlot, Invitrogen, Carlsbad, CA, 
USA). Membranes were blocked in 5% BSA in Tris buffered 
saline (TBS) containing 0.05% Tween-20. Primary antibod-
ies for this study include iNOS (Abcam, MA; Ab15323, 
1:250), CLEC7A (Novus Biologicals, CO; NBO1-45514, 
1:500), P2RY12 (Novus Biologicals, CO; NBP1-69246, 
1:500), CD11c (Novus Biologicals, CO; MAB6950, 1:250), 
and β-actin (Santa Cruz, CA; AC-15, 1:10,000). Bound 
antibody was detected using InfraRed detectable secondary 
antibodies (LI-COR, NE; 1:10,000), using LI-COR Odyssey 
infrared scanner for imaging (LI-COR, Lincoln, NE, USA). 
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Blots were analyzed using NIH ImageJ software and normal-
ized against the housekeeper protein.
Enzyme Linked Immunosorbent Assay (ELISA)
IL-1β was measured from HBMVEC-conditioned media, 
and TNFα and IL-6 were measured from BV-2 superna-
tant, using Enzyme Linked Immunosorbent Assay (ELISA) 
from Biolegend (San Diego, CA, USA; Human IL-1β cat. 
#437004, Mouse TNFα cat. #430904, Mouse IL-6 cat. 
#431304). The protocol provided by the manufacturer was 
followed, without modifications. At the conclusion of the 
assay, absorbance was detected at 570 nm and 450 nm using 
Synergy HTX multi-mode reader (Biotek Instruments, Win-
ooski, VT, USA).
Gelatin Zymography
Gelatin zymography was performed as previously described 
(Thirumangalakudi et al. 2007) to assess the activity of 
MMP-9 in BV-2 supernatant following treatments. Briefly, 
samples were run on 10% Gelatin Zymogram Plus Protein 
Gels (Invitrogen, Carlsbad, CA, USA). Following electro-
phoresis, gels were incubated at room temperature (RT) with 
zymogram renaturing buffer (Novex, Carlsbad, CA, USA) 
for 30 min, and then incubated with zymogram developing 
buffer (Novex, Carlsbad, CA, USA) for 30 min. Gels were 
further incubated with fresh developing buffer overnight at 
37 °C. Gels were stained with Coomassie Blue R250 for 
1 h, and de-stained in deionized water for 1 day. Images 
scanned on Epson Scanner (Epson, Long Beach, CA, USA) 
and analyzed using ImageJ.
Phagocytosis Assay
Analysis of phagocytic activity of BV-2 was done by meas-
uring uptake of fluorescently labeled beads. Protocol for the 
phagocytosis assay was derived from previously published 
works (Lucin et al. 2013; Lian et al. 2016; Cai et al. 2017; 
Zhang et al. 2017) with modifications. BV-2 cells were 
plated in 8-well chamber slides at a density of 10,000 cells 
per well in DMEM with 10% FBS and grown for 48 h. Cells 
were treated as before with HBMVEC-conditioned media 
for 24 h.
Preopsonized latex beads of 1 um diameter (Sigma, cat. 
#L2778-1ML) were prepared in PBS with 50% FBS at 10% 
(v/v) for 1 h at 37 °C. Beads were then further diluted 1:100 
in DMEM to make a 0.01% (v/v) beads and 0.05% (v/v) 
FBS solution.
At the conclusion of 24 h treatment, BV-2 media was 
removed and 500 uL of bead solution was added to each well 
for 1 h at 37 °C. Beads were then removed and cells were 
rinsed three times with cold PBS. Cells were fixed with 4% 
paraformaldehyde (PFA) in PBS (200 uL per well) for 4 min 
at RT. PFA was removed, cells were then blocked and per-
meabilized with 5% horse serum and 0.3% Triton X-100 in 
PBS (200 uL per well) for 30 min at RT. Cells were washed 
again with cold PBS three times.
To image, antifade mounting solution with DAPI (Invit-
rogen, cat. #S36964) was added, slide was covered with a 
cover slip, and sealed. Beads were imaged at 575–610nm 
(red) and DAPI at 345–453 nm (blue) using the EVOS® 
FL Auto Cell Imaging System (ThermoFisher Scientific, 
Waltham, MA, USA). ImageJ was used to quantify red/blue 
in all images.
Statistical Analysis
Data were analyzed for significance using one-way analysis 
of variance (ANOVA) and multiple comparisons carried out 
using the post-hoc Bonferroni test on GraphPad Prism (ver-
sion 8.01). Data are represented as Mean +/− SEM. Groups 
contain n = 6 unless otherwise specified.
Results
Injury of Brain Endothelial Cells by Exposure to High 
Glucose Levels and Hypoxia
HBMVECs were either treated with 30 mM glucose (6 h), 
exposed to hypoxia (1 h), or exposed to hypoxia plus high 
glucose (6 h). LDH release in the supernatant was meas-
ured to estimate lethal cell injury. Treatment of cells with 
glucose evoked a small but not significant increase in LDH 
release. In contrast, hypoxia exposure significantly increased 
LDH release compared to untreated controls (p < 0.001). 
The level of LDH detected in cells exposed to hypoxia plus 
high glucose was higher than levels measured in response to 
hypoxia alone (Fig. 1a).
To explore indices of non-lethal injury the generation of 
ROS and release of the inflammatory mediator IL-1β were 
assessed. HBMVECs analyzed using the fluorescent probe 
DCF-DA to measure ROS showed that glucose treatment did 
not alter ROS production compared to control cells, while 
hypoxia exposure increased ROS levels relative to control, 
but the increase was not significant. HBMVECs exposed 
to both glucose and hypoxia showed significantly increased 
production of ROS compared to control (p < 0.001), glucose 
(p < 0.001), or hypoxia (p < 0.05) (Fig. 1b). Measurement 
of IL-1β levels in supernatant by ELISA indicated that treat-
ment with glucose increased IL-1β levels, but the increase 
was not significant (p = 0.11), while hypoxia exposure did 
not affect IL-1β levels. Interestingly, the combination of glu-
cose treatment and hypoxia exposure appeared to mitigate 
the increase evoked by glucose alone (Fig. 1c).
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Injured Brain Endothelial Cells Increase Reactive 
Nitrogen Species Production in BV‑2 Cells
To determine whether injured endothelial cells can affect 
reactive nitrogen species (RNS) generation in microglia, 
the microglial cell line BV-2 was treated with HBMVEC-
conditioned media for 24 h. The Griess assay was used to 
assess NO production in the BV-2 supernatant (Fig. 2a) and 
inducible nitric oxide synthase (iNOS) levels in BV-2 lysates 
were analyzed by western blot (Fig. 2b).
BV-2 cells exposed to conditioned media from glucose-
treated endothelial cell cultures (EC-G) showed a significant 
increase in both NO production (p < 0.001) (Fig. 2a) and 
iNOS expression (p < 0.001) (Fig. 2b) compared to BV-2 
cells incubated with untreated endothelial cell conditioned 
media. In contrast, treatment of BV-2 cells with conditioned 
media from hypoxia-exposed endothelial cells (EC-H) did 
not affect either NO production or iNOS levels (Fig. 2a, 
b). Treatment of BV-2 cells with conditioned media from 
endothelial cells exposed to both glucose and hypoxia (EC-
G+H) significantly increased NO production compared to 
BV-2 cells exposed to conditioned media from only glucose-
treated endothelial cell cultures (p < 0.001). There was no 
significant difference in BV-2 iNOS levels evoked by con-
ditioned media from endothelial cells treated with glucose 
alone and media derived from endothelial cells exposed to 
both glucose and hypoxia (Fig. 2b).
Glucose‑Injured Microvascular Endothelial Cells 
Induce Changes in Inflammatory Proteins Released 
from BV‑2 Cells
The release of cytokines, TNFα and IL-6, by BV-2 cells 
treated with HBMVEC-conditioned media for 24 h was 
assessed by ELISA.
BV-2 cells that were treated with media from glucose-
injured endothelial cells (EC-G) released a significantly 
(p < 0.001) higher level of the pro-inflammatory cytokine 
Fig. 1  HBMVEC injury following treatment with high glucose with 
and without hypoxia HBMVECs were exposed to high glucose (6 h), 
hypoxia (1 h), or a combination of both (6 h). Cells and supernatant 
were collected to assess measures of cellular injury: a lactate dehy-
drogenase (LDH) release as a measure of cell toxicity, b reactive oxy-
gen species (ROS) production measured with DCF-DA, represented 
as relative fluorescence units (RFU), and (C) IL-1β secretion in the 
supernatant measured by ELISA. ***p < 0.001 vs. Control, ###p < 
0.001 vs. Glucose, ^p < 0.05 vs. Hypoxia
Fig. 2  HBMVEC injury 
induces increased nitric oxide 
production by BV-2 micro-
glia Conditioned media from 
injured HBMVECs was used to 
treat BV-2 microglia for 24 h. 
Supernatant and cell lysate were 
collected following treatments 
and used to measure (a) Nitric 
Oxide (NO) in the supernatant 
using Griess reagent (n = 12 
per group) and (b) expression of 
iNOS in the lysate by western 
blot. **p < 0.01 vs. Control, 
***p < 0.001 vs. Control, ###p 
< 0.001 vs. Glucose, ^p < 0.05 
vs. Hypoxia, ^^^p < 0.001 vs. 
Hypoxia.
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TNFα compared to microglial cells exposed to control 
conditioned media (Fig.  3a). On its own, conditioned 
media from hypoxic-injured endothelial cells (EC-H) did 
not alter BV-2 production of TNFα. However, media from 
endothelial cells that were exposed to both glucose and 
hypoxia (EC−G+H) increased TNFα production in BV-2 
to higher levels than elicited by media from glucose-only 
injured endothelial cells (p < 0.001) (Fig 3a).
In contrast to the results obtained for TNFα, the data 
showed that conditioned media from glucose-injured 
endothelial cells (EC-G) caused a significant (p < 0.001) 
decrease in the release of IL-6, a complex cytokine with 
both pro- and anti-inflammatory activities (Fig. 3b). Con-
ditioned media from hypoxic-injured endothelial cells 
(EC-H) did not affect BV-2 IL-6 levels. Also, media from 
endothelial cells exposed to both glucose and hypoxia 
(EC−G+H) showed a decrease in IL-6 release that was 
comparable to that observed for glucose alone (EC-G) 
(Fig. 3b).
Supernatant from BV-2 cells was collected following 
treatment with HBMVEC-conditioned media for 24 h, as 
described above, and MMP-9 activity measured by gel 
zymography. Conditioned media from hypoxia exposed 
endothelial cells (EC-H) did not affect MMP-9 activity 
(Fig. 3c). There was a significant (p < 0.001) increase 
in MMP-9 activity, relative to controls, elicited media 
from glucose only (EC−G) and glucose plus hypoxia 
(EC−G+H) (Fig. 3c).
BV‑2 Treated with Conditioned Media from Injured 
Brain Endothelial Cells Show Altered Expression 
of Microglia Activation Markers
BV-2 cells were treated with HBMVEC-conditioned media 
for 24 h, as described above, and western blot used to deter-
mine changes in protein expression for several microglia 
activation- and DAM-related markers.
Changes in the expression of CD11c and CLEC7A by 
BV-2 in response to endothelial cell conditioned media were 
similar in pattern, differing slightly in magnitude. Condi-
tioned media from glucose-injured endothelial cells (EC-
G) significantly increased expression of CD11c (p < 0.01) 
(Fig. 4a) and CLEC7A (p < 0.01) (Fig. 4b) as did condi-
tioned media from glucose plus hypoxia injury (EC-G+H) 
for both CD11c (p < 0.01) and CLEC7A (p < 0.05). Expo-
sure of BV-2 cells to HBMVEC-conditioned media collected 
as described above did not affect expression of TREM2 (data 
not shown).
Western blot was also used to assess the expression of 
a homeostatic microglia marker, P2RY12. Expression 
of P2RY12 was significantly decreased when BV-2 cells 
were treated with media from glucose injury (EC-G) (p < 
0.001), hypoxic injury (EC-H) (p < 0.01), or glucose plus 
hypoxic injury (EC-G+H) (p < 0.001) compared to controls 
(Fig. 4c). Together, these changes indicate a shift towards a 
DAM phenotype in the BV-2 treated with conditioned media 
from damaged brain endothelial cells.
Fig. 3  HBMVEC injury induces increased production of inflamma-
tory mediators by BV-2 microglia Conditioned media from injured 
HBMVECs was used to treat BV-2 microglia for 24 h. Supernatant 
from BV-2 was collected following treatments. ELISA was used to 
measure secretion of (a) TNFα and (b) IL-6. (c) The enzymatic activ-
ity of MMP-9 was measured by gel zymography (n = 3 per group). 
***p < 0.001 vs. Control, ###p < 0.001 vs. Glucose, ^^^p < 0.001 vs. 
Hypoxia.
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The Phagocytic Ability of BV‑2 Cells is Altered 
in Response to Conditioned Media from Injured 
Endothelial Cells
BV-2 cells were treated for 24 h with HBMVEC-condi-
tioned media, as described above, and uptake of fluores-
cently labeled beads measured to assess phagocytic abil-
ity (Fig. 5a and b). Bead uptake by BV-2 cells treated with 
glucose injury media (EC-G) was significantly increased 
(p < 0.05) compared to controls. In contrast, conditioned 
media from hypoxic injury (EC−H) did not significantly 
alter phagocytic ability of BV-2 cells. However, treatment 
of BV-2 with conditioned media from glucose plus hypoxia 
injury (EC−G+H) significantly (p < 0.001) reduced the 
phagocytic response compared to glucose injury alone con-
ditioned media (EC-G) (Fig. 5c).
Discussion
The results of this study demonstrate that injured brain 
endothelial cells can negatively impact the inflammatory/
activation state of microglia. These data highlight the impor-
tance of cellular cross-talk in the brain, especially among 
cells in the NVU. The ability of injured endothelial cells to 
induce changes in microglia, consistent with microglia alter-
ations observed in AD, suggests that this cell-cell interaction 
is contributory to the development of pathology in AD.
Our data show that brain endothelial cells injured by glu-
cose and hypoxia induce increases in microglial production 
of NO and TNFα. These inflammatory mediators have been 
well documented to be elevated in the AD brain in several 
cell types, including microglia (Hickman et al. 2018). Simi-
larly, our results showing increases in microglial MMP-9 
expression by injured endothelial cell conditioned media 
are consistent with literature documenting elevated MMP-9 
in AD (Lorenzl et al. 2003). These results suggest that an 
injured endothelium may promote the transition of microglia 
toward an inflammatory phenotype.
Microglia were previously classified dichotomously into 
M1 and M2 phenotypes using Iba1 as a marker to identify 
“activated” microglia (Ito et al. 1998). Based on compre-
hensive gene expression profiling and functional studies, 
a more fluid spectrum of activation states has been recog-
nized to exist, with the DAM phenotype identified in the 
AD brain. The DAM phenotype exhibits downregulation of 
homeostatic microglia genes and upregulation of pro-inflam-
matory and neurodegeneration-associated genes (Keren-
Shaul et al. 2017; Krasemann et al. 2017). Our findings that 
injured endothelial cells significantly increase microglial 
expression of DAM-related markers CD11c and CLEC7A, 
as well as decrease expression of the homeostatic marker 
P2RY12, suggest conversion of microglia towards a DAM-
like phenotype.
Interestingly, treatment of microglial cultures with con-
ditioned media from injured endothelial cells did not affect 
the expression of TREM2. Although mutations in TREM2 
are related to increased AD risk, its precise role is unclear 
(Jay et al. 2017). One could interpret the lack of effect on 
TREM2 as a peculiarity related to BV-2 cells and not indic-
ative of microglia in vitro or in vivo. Although there are 
limitations in using an immortalized cell system to approxi-
mate primary cell behavior in vitro, BV-2 cells have been 
shown to closely model the inflammatory response of pri-
mary microglia in vitro (Stansley et al. 2012). In addition, 
the response of BV-2 cells to LPS has substantial overlap 
to the response of primary cultured microglia as well as to 
that of microglia in vivo (Henn et al. 2009). A recent study 
documented that conversion of microglia to the DAM phe-
notype occurs in a TREM-independent phase followed by a 
Fig. 4  BV-2 treated with conditioned media from injured HBMVEC 
show altered expression of microglia activation markers Conditioned 
media from injured HBMVECs was used to treat BV-2 microglia for 
24 h. Western blot was used to assess the expression of microglia 
markers, (a) CD11c, (b) CLEC7A, and (c) P2RY12. *p < 0.05 vs. 
Control, **p < 0.01 vs. Control, ***p < 0.001 vs. Control, ^p < 0.05 
vs. Hypoxia, ^^p < 0.01 vs. Hypoxia
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TREM-dependent phase (Keren-Shaul et al. 2017). It is pos-
sible that in our study the transition to the DAM phenotype 
is not yet complete.
Phagocytosis is a key aspect of microglial function in 
the healthy brain, responsible for clearance of debris, 
apoptotic cells, and synaptic pruning (Fu et al. 2014; Hick-
man et al. 2018). In AD, phagocytic microglia may help 
to clear aggregated amyloid-β (Aβ) and be beneficial (Fu 
et al. 2014). In this regard, increased phagocytic activity is 
correlated with enhanced production of anti-inflammatory 
and reduced production of pro-inflammatory mediators in 
microglia and macrophages (Fadok et al. 1998; Wolf et al. 
2017; Janda et al. 2018). However, there is still some debate 
as to whether microglia phagocytosis is beneficial or detri-
mental in disease. For example, TREM2 mediated phago-
cytosis of apoptotic neurons is associated with decreased 
a decreased pro-inflammatory response (Takahashi et al. 
2005), while myelin debris phagocytosis enhanced the pro-
inflammatory and dampened the anti-inflammatory profile 
in microglia (Siddiqui et al. 2016). TREM2 knock out mice 
have impaired phagocytosis, related to increased Aβ plaque 
burden, reduced microglia localization to plaques, and 
increased neuritic dystrophy ( Jay et al. 2017; Hickman et al. 
2018). DAM exhibit upregulation of phagocytosis-related 
genes (Keren-Shaul et al. 2017), while other studies indi-
cate that an anti-inflammatory DAM sub-type highly express 
phagocytosis-associated genes (Rangaraju et al. 2018). Here, 
the response of BV-2 cells to conditioned media from injured 
endothelial cells appears to be related to the nature of the 
endothelial insult. The data show that microglial phagocy-
tosis is increased in response to conditioned media from 
glucose-injured endothelial cells. In contrast, conditioned 
media from hypoxia-injured endothelial cells does not 
significantly alter phagocytosis and further, media from 
glucose plus hypoxic injured endothelial cells reduces the 
increase in phagocytosis evoked by glucose alone. These 
data are similar to the results showing that glucose but not 
hypoxia increases IL-1β release from endothelial cells and 
Fig. 5  BV-2 treated with conditioned media from injured HBMVEC 
show altered phagocytic ability Conditioned media from injured 
HBMVEC was used to treat BV-2 microglia for 24 h. BV-2 were then 
incubated with fluorescently labeled beads for 1 h. Cells were then 
imaged (EC-C, EC-G, EC-H, EC-G+H left to right) at 10X (a) and 
20X (b) and bead uptake per cell was quantified (c) as a measure of 
phagocytic activity. *p < 0.05 vs. Control, ###p < 0.001 vs. Glucose.
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that concurrent hypoxia plus glucose reduces the increase 
in IL-1β produced by glucose alone. These results support 
the idea that IL-1β from injured endothelial cells promotes 
increased phagocytosis by microglia. Other studies have 
also linked IL-1β to increased microglial phagocytosis as 
well as to microglial autophagy, a process closely linked 
to phagocytosis (Ferreira et al. 2011; François et al. 2013; 
Plaza-Zabala et al. 2017).
Considerable evidence documents an injured cerebro-
vasculature in AD (Grammas 2011). We have previously 
shown that damaged brain endothelial cells secrete a num-
ber of factors that have been related to neuroinflammation 
and the activation of pro-inflammatory microglia, includ-
ing thrombin, MMPs, and a number of cytokines (Grammas 
and Ovase 2001; Grammas and Ovase 2002; Grammas et al. 
2004; Grammas et al. 2011; K Lee et al. 2015; Krasnow 
et al. 2017). Our findings indicate a role for vascular-derived 
IL-1β and ROS in propagating the inflammatory cycle in the 
brain. Here, brain endothelial cells injured by glucose and 
glucose plus hypoxia exhibit an upregulation in IL-1β and 
ROS, respectively, and these increases were correlated with 
the up-regulation of pro-inflammatory markers in micro-
glia. IL-1β acts as an amplifier of immune reactions and can 
stimulate a number of downstream neuroinflammatory pro-
cesses. In the periphery, IL-1β stimulated the differentiation 
of monocytes to M1-like macrophages (Bent et al. 2018). 
In vitro, IL-1β enhanced microglia release of NO following 
LPS stimulation (Possel et al. 2000). High levels of oxidative 
stress have been identified in the AD brain, and ROS func-
tion as mediators of injury and inflammation (Fischer and 
Maier 2015). ROS-mediated signaling pathways are relevant 
for the induction of inflammatory signaling, including the 
stimulation of pro-inflammatory cytokines and NO (Fischer 
and Maier 2015). TNFα, NO, and MMP-9 are all produced 
in response to both oxidative stress and cytokine signaling 
(Yong et al. 2001; Clark et al. 2010; Hsieh and Yang 2013; 
Fischer and Maier 2015), highlighting the potential for these 
endothelial-derived mediators to activate a pro-inflammatory 
response in microglia similar to that shown in our in vitro 
system.
Endothelial cells may react to injurious stimuli such as 
glucose and hypoxia by activating multiple signaling path-
ways resulting in the release of diverse mediators (Eelen 
et al. 2015). In some instances, these mediators could syner-
gize, as we observed for NO release by microglia which was 
higher when treated with conditioned media from glucose 
plus hypoxic injury compared to glucose alone. In contrast, 
the combination of hypoxic and glucose injury reduced the 
increase in microglial phagocytosis evoked by glucose-only 
injured endothelial cells. Finally, the responses of cytokines 
as a family may also vary with individual proteins. In this 
regard, while TNFα expression by microglia was increased 
by glucose-injured endothelial cells, IL-6 expression was 
significantly inhibited. Although mostly regarded as a pro-
inflammatory cytokine, IL-6 also has many regenerative or 
anti-inflammatory activities (Scheller et al. 2011). The pleio-
tropic actions of IL-6 as both a proinflammatory mediator as 
well as a neurotrophic factor involved in the physiological 
homeostasis of the CNS further highlight the complexity 
of cellular responses in the presence of multiple bioactive 
moieties.
The relationship between brain endothelial cells and 
microglia is a growing area of interest, with early findings 
indicating that damage to brain endothelial cells by a num-
ber of mediators can induce an inflammatory response in 
microglia. Microglia treated with conditioned media from 
IL-1-treated endothelial cells exhibit increased expression of 
inflammatory mediators, including IL-1β, IL-6, and CCL2 
(Zhu et al. 2019). Treatment of microglia with conditioned 
media from brain endothelial cells exposed to oxygen-
glucose deprivation (OGD) exhibited increases in cytokine 
release, including TNFα, IL-1β, and IL-10. These micro-
glia additionally exhibited upregulated iNOS expression and 
impaired phagocytosis (Xing et al. 2018). The OGD-related 
findings mirror our results in the EC-G and EC-GH micro-
glia treatment groups, particularly with respect to increases 
in TNFα and iNOS, as well as altered phagocytic ability. 
Together, these studies further support our hypothesis that 
the damaged cerebrovasculature can be a driver of inflam-
mation in the brain, and indicate that damage by different 
mediators may activate diverse inflammatory responses in 
microglia.
Conclusions
The results of this study are important as they shed light on 
the interaction of two cell types, endothelial cells and micro-
glia, likely important in the development of AD pathology. 
The role of specific mediators in this cell-cell communica-
tion is difficult to ascribe because of the inherent limitations 
of using a simplified in vitro system. Nevertheless, the dem-
onstration that injury to brain endothelial cells by glucose 
and hypoxia, two insults that are relevant for diabetes, affects 
processes in microglia that are relevant for AD, support the 
hypothesis that the cerebral microcirculation could be a 
nidus where diabetic processes promote the development of 
AD. A more in-depth investigation of how endothelial cell 
damage can alter microglia function and lead to an inflam-
matory response may help us to better understand the neu-
roinflammation found in AD and other neurodegenerative 
disorders. Additionally, greater knowledge of the media-
tors responsible for this endothelial cell-microglia crosstalk 
could inform novel therapeutic targets and techniques for 
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mitigating disease-related inflammation at its potential point 
of origin, the vasculature.
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